Luminex Corporation announced it has signed a global sales and distribution agreement with Life Technologies Corporation for its award-winning Magpix multiplexing instrument for analysis of proteins for research use. Launched in July 2010, Magpix is a compact multiplex analyser that can quickly, accurately and reproducibly detect 50 different analytes simultaneously on a single sample, including proteins and nucleic acids.

“We are very pleased to have Life Technologies as a global distribution partner for Magpix. This new, highly innovative instrument is an important advancement in Luminex's goal to create multiplexing solutions for a range of applications and for laboratories of all sizes,” said Michael F Pintek, senior vice president of operations for Luminex. “With its global scope, Life Technologies helps ensure that this advanced multiplexing solution reaches the right scientists and researchers. This partnership will help accelerate science and improve the efficiency of disease-related research around the world.”

Providing nearly 5,000 data points in under an hour, Magpix was designed to meet the needs of laboratories, academic researchers and scientists who, until now, have not been able to take advantage of the power of multiplexing because of resource and space limitations. Based on Luminex's xMAP technology, the easy-to-use Magpix instrument is compact - comparable in size to a desktop computer - making it attractive to a broad array of laboratories and institutions. Due to its adaptability, the instrument can advance research across many disease states by bringing many types of multiplexing applications to scientists. Additionally, Magpix allows users of legacy approaches, such as ELISA and Western Blot, to enjoy the advantages of xMAP Technology for single analyte or multiplexed testing.

“Life Technologies is pleased to be a partner in the global distribution of the Magpix instrument,” said Peter Dansky, president of Molecular and Cell Biology at Life Technologies. “Magpix represents a unique platform through which Life Technologies can make its cutting-edge antibody content accessible for a broad range of protein quantitation needs in basic and clinical research.”

Magpix saves vital time in the laboratory, produces faster, accurate, reproducible results and requires less sample input than existing legacy technologies such as ELISA and Western blot. Like other Luminex instruments, Magpix is versatile and flexible and can be used to analyse both nucleic acids and proteins, making it applicable in many research settings. It is easy to install out of the box and weighs less than 40 lbs., approximately 18 kg, making it simple and affordable to ship and deploy anywhere in the world.

Magpix was awarded a prestigious 2011 Medical Design Excellence Award for Innovative Design and Contribution and recently received CE IVD mark in Europe.

Magpix is for research use only in the United States. Not for use in diagnostic procedures.

Luminex Corporation develops, manufactures, and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries.

Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. The company manufactures both molecular diagnostic and research use only products.